C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

J.O. Rinne; D.J. Brooks; M.N. Rossor; N.C. Fox; R. Bullock; W.E. Klunk; C.A. Mathis; K. Blennow; J. Barakos; A.A. Okello; S.R.M. de Llano; E. Liu; M. Koller; K.M. Gregg; D. Schenk; R. Black; M. Grundman

doi:10.1016/S1474-4422(10)70043-0

C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

J.O. Rinne
, D.J. Brooks
, M.N. Rossor
, N.C. Fox
, R. Bullock
, W.E. Klunk
, C.A. Mathis
, K. Blennow
, J. Barakos
, A.A. Okello
, S.R.M. de Llano
, E. Liu
, M. Koller
, K.M. Gregg
, D. Schenk
, R. Black
, M. Grundman

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	363-372
Journal	Lancet neurology
Volume	9
Issue number	4
DOIs	https://doi.org/10.1016/S1474-4422(10)70043-0
Publication status	Published - 2010

Access to Document

10.1016/S1474-4422(10)70043-0

Cite this

Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., de Llano, S. R. M., Liu, E., Koller, M., Gregg, K. M., Schenk, D., Black, R., & Grundman, M. (2010). C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet neurology, 9(4), 363-372. https://doi.org/10.1016/S1474-4422(10)70043-0

@article{97a3cc07786746aa849feafafd410b2a,

title = "C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study",

author = "J.O. Rinne and D.J. Brooks and M.N. Rossor and N.C. Fox and R. Bullock and W.E. Klunk and C.A. Mathis and K. Blennow and J. Barakos and A.A. Okello and \{de Llano\}, S.R.M. and E. Liu and M. Koller and K.M. Gregg and D. Schenk and R. Black and M. Grundman",

year = "2010",

doi = "10.1016/S1474-4422(10)70043-0",

language = "Undefined/Unknown",

volume = "9",

pages = "363--372",

journal = "Lancet neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "4",

}

Rinne, JO, Brooks, DJ, Rossor, MN, Fox, NC, Bullock, R, Klunk, WE, Mathis, CA, Blennow, K, Barakos, J, Okello, AA, de Llano, SRM, Liu, E, Koller, M, Gregg, KM, Schenk, D, Black, R & Grundman, M 2010, 'C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study', Lancet neurology, vol. 9, no. 4, pp. 363-372. https://doi.org/10.1016/S1474-4422(10)70043-0

C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. / Rinne, J.O.; Brooks, D.J.; Rossor, M.N. et al.
In: Lancet neurology, Vol. 9, No. 4, 2010, p. 363-372.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

AU - Rinne, J.O.

AU - Brooks, D.J.

AU - Rossor, M.N.

AU - Fox, N.C.

AU - Bullock, R.

AU - Klunk, W.E.

AU - Mathis, C.A.

AU - Blennow, K.

AU - Barakos, J.

AU - Okello, A.A.

AU - de Llano, S.R.M.

AU - Liu, E.

AU - Koller, M.

AU - Gregg, K.M.

AU - Schenk, D.

AU - Black, R.

AU - Grundman, M.

PY - 2010

Y1 - 2010

U2 - 10.1016/S1474-4422(10)70043-0

DO - 10.1016/S1474-4422(10)70043-0

M3 - Article

SN - 1474-4422

VL - 9

SP - 363

EP - 372

JO - Lancet neurology

JF - Lancet neurology

IS - 4

ER -